🏛️ Verified NIH Record • Updated 2026-03-02

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT04819100)

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company

🩺 Plain-English Summary (8th-Grade Level)

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.

Who can join: Review the eligibility criteria below.

Location: UCLA Hematology/Oncology - Santa Monica — Los Angeles, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (211 Sites)

Showing the first 25 of 211 sites.

  • UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
  • Stockton Hematology Oncology Group — Stockton, California
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, California
  • GenesisCare — Aventura, Florida
  • GenesisCare - Boca Raton — Boca Raton, Florida
  • USO-Cancer Care Center of Brevard, Inc. — Palm Bay, Florida
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
  • USO-New York Oncology Hematology, P.C — Latham, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • USO - Alliance Cancer Specialists, PC — Horsham, Pennsylvania
  • Sarah Cannon Research Institute SCRI — Nashville, Tennessee
  • Tennessee Oncology Nashville — Nashville, Tennessee
  • USO-Texas Oncology-Central/South Texas — Austin, Texas
  • US Oncology — The Woodlands, Texas
  • Sunshine Coast University Hospital — Birtinya, Queensland
  • Rockhampton Hospital — Rockhampton, Queensland
  • The Townsville Hospital — Townsville, Queensland
  • Ballarat Health Services — Ballarat Central, Victoria
  • Bendigo Health Care Group — Bendigo, Victoria
  • Goulburn Valley Health — Shepparton, Victoria
  • South West Healthcare — Warrnambool, Victoria
  • Border Medical Oncology — Wodonga, Victoria
  • Landeskrankenhaus Feldkirch — Feldkirch, Vorarlberg
  • Klinik Floridsdorf — Vienna,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Non-Small-Cell Lung

Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗